CClinicalTrials.gg
CompletedNCT02752165TEAM-EDUpdated Sep 5, 2025Results posted

Telemedicine Enhanced Asthma Management Through the Emergency Department

An interventional study of TEAM-ED and Enhanced Usual Care in Asthma, sponsored by University of Rochester. Completed at 1 site in United States. Open to participants aged 3 Years to 12 Years. Per ClinicalTrials.gov, last updated 2025-09-05.

Sponsored by University of Rochester · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
384
Allocation
Randomized
Ages
3 Years to 12 Years
Sex
All
01

Study summary

In the US, children from minority ethnic and racial backgrounds suffer disproportionately from asthma and account for substantially more emergency department (ED) visits and hospitalizations than non-minority children. While NHLBI guidelines recommend daily preventive medications for all children with persistent asthma to prevent morbidity as well as ED visits and hospitalizations, many children who should receive preventive medications are not receiving them. This is in part because children presenting to the ED for an acute asthma exacerbation rarely receive preventive asthma care, due to the ED's focus on acute, episodic care. The NHLBI guidelines recommend that children follow-up with a primary care provider (PCP) within 1-4 weeks of the ED visit. The post-ED follow-up visit is an opportunity for the PCP to prescribe effective preventive asthma medications, step-up medication for children who demonstrate poor control, promote adherence, and provide education on asthma self-management and trigger control. However, rates for follow-up after an asthma-related ED visit are extremely low, and preventive care is delivered inconsistently even when children are seen in follow-up. In the investigators' prior work they have found that a provider prompting intervention can enhance the delivery of guideline-based preventive asthma treatments at the time of a primary care office visit and ultimately reduce morbidity. They have also found that telemedicine can link children with persistent asthma to a provider for optimal chronic illness management. The goal of this project is to use a novel telemedicine-based program to facilitate primary care follow-up and promote the delivery of guideline-based preventive care for high-risk children presenting to the ED for an asthma exacerbation. The investigators will utilize a 2-group randomized trial to test the TEAM-ED intervention. The intervention includes: 1) a telemedicine assessment at the child's school within one week of discharge from the ED and completed by a PCP, 2) 'point-of-care' prompting to promote the provision of guideline-based preventive care during the telemedicine visit, and 3) two additional telemedicine-assisted follow-up assessments to assure optimal response to treatment and tailor the care regimen as needed. The investigators will assess the effectiveness of the program in reducing respiratory morbidity and improving preventive asthma care, with follow-up assessments at 3, 6, 9, and 12 months.

02

Conditions studied

  • Asthma

Browse trials for

03

In context

Asthma

3,921 studies on the registry are indexed under Asthma; 507 are open to participants now.

This study's enrollment of 384 is above the median of 83 across 2,752 interventional studies indexed under Asthma.

Browse Asthma studies →

Lead sponsor

University of Rochester is the lead sponsor of 715 studies on the registry; 116 are open to participants now.

Of its 56 completed or terminated interventional studies of FDA-regulated products, 44 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Prior physician diagnosis of asthma
  • current emergency visit for an acute asthma exacerbation, requiring nebulized albuterol therapy
  • Persistent or poor control of asthma, defined by NHLBI guidelines

Exclusion criteria

Exclusion Criteria:

  • Inability to speak and understand either English or Spanish
  • No access to a phone for follow-up surveys
  • Participation in another asthma study at the time of enrollment, or a sibling participating in this or another study Other significant medical conditions that could interfere with assessment of asthma-related measures
  • children in foster care or other situations in which consent cannot be obtained from a legal guardian
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
384 participants (actual)

Study arms

  • Experimental
    TEAM-ED Intervention Group

    Facilitation of preventive asthma management through telemedicine assessment and follow-ups in addition to guideline-based provider prompting

    Other: TEAM-ED

  • Active comparator
    Enhanced Usual Care

    Report of symptoms to primary care physician

    Other: Enhanced Usual Care

Interventions

  • OtherTEAM-ED

    Facilitation of preventive asthma management through telemedicine assessment and follow-ups in addition to guideline-based provider prompting

  • OtherEnhanced Usual Care

    Report of symptoms to primary care physician

06

What researchers measure

Primary outcomes

  1. Number of Symptom-Free Days in the Prior 2 Weeks

    Number of days without symptoms in the prior 2 weeks

    Time frame: At the 3-month follow-up assessment

  2. Number of Symptom-Free Days in the Prior 2 Weeks

    Number of days without symptoms in the prior 2 weeks

    Time frame: At the 6-month follow-up assessment

  3. Number of Symptom-Free Days in the Prior 2 Weeks

    Number of days without symptoms in the prior 2 weeks

    Time frame: At the 9-month follow-up assessment

  4. Number of Symptom-Free Days in the Prior 2 Weeks

    Number of days without symptoms in the prior 2 weeks

    Time frame: At the 12-month follow-up assessment

07

Results

Posted Feb 12, 2024

Participant flow

Recruitment occurred in two emergency departments in Rochester, NY in 2016-2021.

Participant flow — Overall Study
MilestoneTEAM-ED Intervention GroupEnhanced Usual Care
Started191193
Completed146144
Not completed4549
Withdrew: Withdrawal by subject66
Withdrew: Protocol violation65
Withdrew: Lost to follow-up3338

Outcome measures

PrimaryNumber of Symptom-Free Days in the Prior 2 Weeks

Number of days without symptoms in the prior 2 weeks

Time frame:
At the 3-month follow-up assessment
Reported as:
Mean · days
Number of Symptom-Free Days in the Prior 2 Weeks
daysTEAM-ED Intervention GroupEnhanced Usual Care
Number of Symptom-Free Days in the Prior 2 Weeks9.5 ± 4.910.1 ± 4.6
PrimaryNumber of Symptom-Free Days in the Prior 2 Weeks

Number of days without symptoms in the prior 2 weeks

Time frame:
At the 6-month follow-up assessment
Reported as:
Mean · days
Number of Symptom-Free Days in the Prior 2 Weeks
daysTEAM-ED Intervention GroupEnhanced Usual Care
Number of Symptom-Free Days in the Prior 2 Weeks10.2 ± 4.610.4 ± 4.3
PrimaryNumber of Symptom-Free Days in the Prior 2 Weeks

Number of days without symptoms in the prior 2 weeks

Time frame:
At the 9-month follow-up assessment
Reported as:
Mean · days
Number of Symptom-Free Days in the Prior 2 Weeks
daysTEAM-ED Intervention GroupEnhanced Usual Care
Number of Symptom-Free Days in the Prior 2 Weeks10.4 ± 4.610.5 ± 4.3
PrimaryNumber of Symptom-Free Days in the Prior 2 Weeks

Number of days without symptoms in the prior 2 weeks

Time frame:
At the 12-month follow-up assessment
Reported as:
Mean · days
Number of Symptom-Free Days in the Prior 2 Weeks
daysTEAM-ED Intervention GroupEnhanced Usual Care
Number of Symptom-Free Days in the Prior 2 Weeks10.3 ± 4.810.0 ± 4.7

Adverse events

Collected over 1 year. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TEAM-ED Intervention Group0/185 (0%)0/185 (0%)0/185 (0%)
Enhanced Usual Care0/189 (0%)0/189 (0%)0/189 (0%)

Baseline characteristics

10 participants were excluded from analysis as we later learned they did not meet the eligibility criteria.

Age, Continuous
Age, Continuous(years)TEAM-ED Intervention GroupEnhanced Usual CareTotal
Mean6.3 ± 2.66.5 ± 1.86.4 ± 2.7
Sex: Female, Male
Sex: Female, Male(Participants)TEAM-ED Intervention GroupEnhanced Usual CareTotal
Female7475149
Male111113224
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TEAM-ED Intervention GroupEnhanced Usual CareTotal
Hispanic or Latino6457121
Not Hispanic or Latino121131252
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TEAM-ED Intervention GroupEnhanced Usual CareTotal
American Indian or Alaska Native101
Asian325
Native Hawaiian or Other Pacific Islander000
Black or African American94106200
White171532
More than one race303262
Unknown or Not Reported403373
Region of Enrollment
Region of Enrollment(participants)TEAM-ED Intervention GroupEnhanced Usual CareTotal
United States185188373
Mean Symptom-Free Days in prior 2 weeks
Mean Symptom-Free Days in prior 2 weeks(days)TEAM-ED Intervention GroupEnhanced Usual CareTotal
Mean6.61 ± 4.96.88 ± 4.66.7 ± 4.8
08

Study locations

1 site
  • University of Rochester
    Rochester, New York 14642, United States
09

References and documents

Publications

  • Halterman JS, Fagnano M, Tremblay P, Butz A, Perry TT, Wang H. Effect of the Telemedicine Enhanced Asthma Management Through the Emergency Department (TEAM-ED) Program on Asthma Morbidity: A Randomized Controlled Trial. J Pediatr. 2024 Mar;266:113867. doi: 10.1016/j.jpeds.2023.113867. Epub 2023 Dec 6. PubMed 38065280 ↗

Study documents

  • Protocol and statistical analysis plan · May 22, 2020
  • Informed consent form · Jan 11, 2021

Documents are hosted by the registry — open the source record to download them.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02752165
Lead sponsor
University of Rochester
Responsible party
Jill Halterman (Professor, University of Rochester) — Principal investigator
First posted
Apr 26, 2016
Start date
Dec 15, 2016
Primary completion
Jul 12, 2022
Completion
Jul 12, 2022
Results posted
Feb 12, 2024
Last update
Sep 5, 2025

Study contacts

JIll Halterman, MD, MPH
principal investigator · University of Rochester
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion